# US 2008/0306124 A1 · Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306124 A1
- Document ID: US20080306124A1
- Status: Published application
- Kind: A1
- Application number: 11/916,610
- Filed: 2006-06-07
- Published: 2008-12-11
- Earliest claimed: 2005-06-08
- Inventors: Rainer Albert; Sven Weiler; Frederic Zecri
- Web page: https://patentgrep.com/patent/US20080306124A1

## CPC

- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/107: with two aryl or substituted aryl radicals attached in positions 2 and 5
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are polycyclic compounds of formula I wherein R1, R2, X, Y and cycle A are as defined in claim 1, which have interesting pharmaceutical properties.

## Claims

### Claim 1

A compound of formula I
wherein
either X is —N═ and Y is —O—; or X is —O— and Y is —N═; or X is CH and Y is O;
is substituted biphenylyl, 4-phenoxy-phenyl or 4-(phenyl-C1-4alkoxy)-phenyl wherein at least one of the phenyl groups is monosubstituted; phenyl substituted by one or more substituents selected from halogen, nitrile, C1-8alkyl, haloC1-8alkyl, C1-8alkoxy, haloC1-8alkoxy, C1-8alkoxy-C1-8alkoxy, C1-8alkyl-C1-8alkoxy, C1-8alkyl-haloC1-8alkoxy, haloC1-8alkyl-C1-8alkoxy, haloC1-8alkyl-haloC1-8alkoxy, haloC1-8alkoxy-C1-8alkoxy, C1-8alkoxy-haloC1-8alkoxy, haloC1-8alkoxy-1-haloC1-8alkoxy, C1-8alkoxy-C1-8alkyl, haloC1-8alkoxy-C1-8alkyl, C1-8alkoxy-haloC1-8alkyl, haloC1-8alkoxy-haloC1-6alkyl, C1-8alkenyloxy, C2-6alkynyloxy, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl, C3-6cycloalkyl-C1-4alkoxy, C3-6cycloalkyl-oxy, phenyl-C1-4alkoxy and heterocyclic-C1-4alkoxy; or substituted 5 or 6-membered heteroaryl;
R2 is C1-6 alkyl optionally substituted by halogen, OH, NH2, C1-4alkoxy or C1-4-alkylcarbonyloxy; amino; carboxy; sulfamoyl; carbamoyl; or HN—CO—C1-4-alkyl; or
R2 is R3—R4—COOH or R3—R4—CONR5R6
wherein R3 is SO2—NH; SO2—N(C1-4alkyl); CO—NH; CO—N(C1-4alkyl); CH2—O; NH—CO; or
N(C1-4-alkyl)CO; and R4 is C1-6alkylene optionally interrupted by O, S or C═CH2 or optionally substituted phenylene or C3-6cycloalkylene; and each of R5 and R6, independently, is hydrogen or C1-6alkyl or R5 and R6 together with the nitrogen atom to which they are bound form a heterocyclic residue, and
ring A may optionally be substituted,
provided that when Y is O, X is —N═ or —CH═ and R2 is SO2NH—R4—COOH wherein R4 is branched C1-6alkylene, then
i. R1 is other than phenyl either monosubstituted by halogen, C1-8alkyl, C1-8alkoxy, haloC1-8alkyl or haloC1-8alkoxy, or disubstituted by one or two substituents selected from halogen, C1-8alkyl and C1-8alkoxy; or
ii. is other than monosubstituted thienyl or furyl
or a physiologically hydrolysable derivative thereof, a salt, hydrate and/or solvate thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein R1 is substituted biphenylyl, 4-phenoxy-phenyl or 4-(phenyl-C1-4alkoxy)-phenyl wherein at least one of the phenyl groups is monosubstituted.

### Claim 3 (depends on 1)

A compound according to claim 1 wherein R2 is C1-6alkyl optionally substituted by halogen, OH, NH2, C1-4alkoxy or C1-4alkylcarbonyloxy; amino; carboxy; sulfamoyl; carbamoyl; or HN—CO—C1-4-alkyl.

### Claim 4 (depends on 1)

A process for the production of a compound of formula I according to claim 1 which process comprises
a) for the production of a compound of formula I wherein X is —N↑ and Y is O and R2 is as defined above, reacting a compound of formula II
wherein ring A and R2 are as defined in claim 1
with a compound of formula III
wherein R1 is as defined above or a functional derivative thereof; or
b) for the production of a compound of formula I wherein X is —N═ and Y is O and R2 is R3—R4—COOH or R3—R4—CONR5R6 wherein R3 is NH—CO or N(C1-4alkyl)CO and R4, R5 and R6 is as defined in claim 1, reacting a compound of formula IV
wherein R1 and ring A are as defined in claim 1 and R′2 is NH2 or NH(C1-4alkyl), with an acylating agent or by following a Sandmeyer reaction; or
c) for the production of a compound of formula I wherein Y is —N═ and X is O, cyclizing in the presence of a Burgess reagent, a compound of formula V
wherein R1, R2 and ring A are as defined in claim 1; or
d) for the production of a compound of formula I wherein Y is O and X is CH, reacting a compound of formula VI
wherein R1 is as defined in claim 1, with a compound of formula VII
wherein R2 is as defined in claim 1; or
e) converting a compound of formula I into another compound of formula I,
and recovering the resulting compound of formula I in free form or in form of a salt, and, where required converting the compound of formula I obtained in free form into the desired salt form or vice versa.

### Claim 5 (depends on 1)

A compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier therefore.

### Claim 7 (depends on 1)

A compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in preventing or treating disorders or diseases mediated by lymphocytes.

### Claim 8 (depends on 1)

A pharmaceutical combination comprising a) a first agent which is a compound of formula I according to claim 1, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent which is an immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic or anti-infectious agent.

### Claim 9 (depends on 1)

A method for preventing or treating disorders or diseases mediated by lymphocytes, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.
